Update: Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada

MT Newswires Live

Apr 29

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.

The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).

The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).

The company's shares were down nearly 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2631550334"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631550334\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631550334?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 12:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631550334","market":"sh","top_or_hot":-1,"title":"Update: Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada","media":"MT Newswires Live","content":"<html><body><p> Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.</p><p>The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).</p><p>The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-29 12:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.</p><p>The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).</p><p>The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).</p><p>The company's shares were down nearly 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BLSP4452.SGD","symbol_name":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2631550334","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631550334","pubTimestamp":1777438178,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dr. Reddy's Laboratories  has received a notice of compliance  from the Canadian regulator, Pharmaceutical Drugs Directorate , approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen  and 4 mg/pen .The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma .The company's shares were down nearly 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4603":"无人机概念股","BK4532":"文艺复兴科技持仓","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4516":"特朗普概念","NOC":"诺斯罗普格鲁曼","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4564":"太空概念","BK4187":"航天航空与国防","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus"},"translate_title":"更新：Dr.Reddy's Laboratories获得监管部门批准在加拿大销售索马鲁肽注射液","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOC":1},"content_text":"Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).The company's shares were down nearly 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}